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Abstract
Background: Cell migration is involved in several pathological processes such as tumor invasion, neoangiogenesis
and metastasis. Microtubules are needed in directional migration.
Methods: To investigate the effects of microtubule-binding agents (paclitaxel, vinblastine, colchicine, podophyllotoxin),
benzophenanthridine alkaloids (sanguinarine, chelerythrine, chelidonine) and other anti-tumor drugs
(homoharringtonine, doxorubicin) on cell migration, we performed the in vitro wound healing assay. The interactions
between selected alkaloids and microtubules were studied via U2OS cells expressing microtubule-GFP markers.
Results: The microtubule-binding natural products paclitaxel, vinblastine, colchicine and podophyllotoxin significantly
altered microtubule dynamics in living cells and inhibited cell migration at concentrations below apparent cytotoxicity.
The benzophenanthridine alkaloid sanguinarine, chelerythrine and chelidonine which affected microtubules in living
cells, did not inhibit cell migration. Homoharringtonine (protein biosynthesis inhibitor) and doxorubicin significantly
inhibited cell migration, however, they did not exert obvious effects on microtubules.
Conclusion: In this study, we demonstrated that microtubule-binding agents are effective anti-migrating agents;
moreover, homoharringtonine and doxorubicin can be referred as anti-migrating agents, but direct microtubule dynamics
are not involved in their mode of action. Our study provides evidence that some alkaloids and other microtubule-binding
natural products may be interesting candidates for the development of novel agents against metastasis.
Keywords: Cell migration, Microtubule, In vitro wound healing assay, Microtubule-binding agents, Benzophenanthridine
alkaloids, Homoharringtonine
Background
Alkaloids, the largest group of secondary metabolites
that produced mainly from plants, animals, bacteria and
fungi, exhibit a board range of pharmacological activities
such as anti-bacterial, anti-inflammatory and anti-cancer
effects [1–5]. With a great diversity of structures, alka-
loids interfere with various molecular targets including
nucleic acids, proteins, biomembranes and neurorecep-
tors, among which the cytoskeleton represents one of
the most important targets [6].
The ability of cells to migrate is essential for many
physiological processes including embryonic development,
wound repair, tumor invasion, neoangiogenesis and me-
tastasis [7, 8]. The involvement of actin cytoskeleton in
cell migration is well established [8]. In response to extra-
cellular cues, the cell initiates the motility by setting up a
front-to-back polarization, followed by a coordinated cycle
of actin polymerization-dependent protrusion, integrin/
actin-mediated focal adhesion and cell body translocation
resulting from actomyosin contractility, which finally leads
to the cell movement [9]. However, the directional migra-
tion also requires the intact microtubule cytoskeleton.
In migrating cells, an asymmetry of the microtubule
network is initially established, which generates the feed-
backs on Rho proteins to promote the generation of
asymmetries in actin contractility and substrate adhe-
sion, resulting in polarization and directional movement
of the cell [10–13]. Microtubules fulfill different roles in
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cellular processes including intracellular transport, cell
division and migration [14–16], making them attractive
targets for natural toxins in cancer research [17, 18].
Microtubule-binding agents (MBAs) are important
components in clinical combination chemotherapy
and applied widely to treat many different kinds of
cancers [19]. Alkaloids constitute the most important
group of MBAs; well-known examples are the
microtubule-stabilizer paclitaxel (a diterpene alkaloid
from Taxus that clinically used in the treatment of
Kaposi’s sarcoma, lung, ovarian and breast cancer)
and the microtubule-destabilizer vinblastine (a vinca
alkaloid from Catharanthus roseus that clinically
applied for Bladder, lung and breast cancer, Hodgkin’s
disease, solid tumors, leukaemia and lymphomas) [20, 21].
In the last few years, the targeting of cell migration has be-
come a therapeutically challenging approach for cancer
treatment and MBAs have also been reported to in-
hibit cell migration by interfering with microtubule
dynamics [22].
In this study, nine cytotoxic natural products (Fig. 1) af-
fecting different molecular targets were investigated con-
cerning their effects on cell migration using an in vitro
wound healing assay, followed by the study of their inter-
actions with microtubules in GFP co-expressing U2OS
cells. These secondary metabolites include 1) sanguinar-
ine, a benzophenanthridine alkaloid from Sanguinaria
canadensis that has anti-infection, anti-heart-failure,
anti-inflammatory and anti-cancer effects via DNA inter-
calation and suppression of NF-KB activation [23–26]; 2)
chelerythrine, a benzophenanthridine alkaloid from Cheli-
donium majus that inhibits the proliferation of neoplasms
and reproduction of bacteria via DNA intercalation and
inhibition of protein kinase C [27, 28]; 3) chelidonine, a
benzophenanthridine alkaloid from Chelidonium majus
that exhibits anti-inflammatory and anti-tumor activities
via inhibition of telomerase and tubulin [29, 30]; 4) homo-
harringtonine, a cephalotaxine alkaloid from Cephalo-
taxus harringtonia that has been approved by FDA for the
treatment of chronic myeloid leukemia via inhibition of
protein synthesis [31, 32]; 5) doxorubicin, an anthracycline
antibiotic from Streptomyces peucetius that has been com-
monly used in cancer therapy such as solid tumors,
leukemia, lymphomas, breast, lung, ovarian, gastric and
liver cancers for more than 40 years via inhibition of topo-
isomerase II [33, 34]. Microtubule-binding natural prod-
ucts such as paclitaxel, vinblastine, colchicine (an alkaloid
from Colchicum autumnale that used for Familial Medi-
terranean fever and acute gout flares [35]) and podophyl-
lotoxin (a lignan from Podophyllum hexandrum that used
to treat Genital warts [36]) were investigated as positive
controls. In this study we can provide evidence for partly
unknown effects of these natural products on cell migra-
tion and their interactions with microtubules.
Methods
Chemicals
Colchicine, podophyllotoxin, dimethyl sulfoxide (DMSO),
fetal bovine serum (FBS), geneticin, 3-(4,5-dimethylthiazo-
l-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were pur-
chased from Sigma-Aldrich (Steinheim, Germany);
Paclitaxel (5.95mg/mL) and vinblastine sulfate (1mg/mL)
were obtained from the Pharmacy of the University Hos-
pital Heidelberg (Heidelberg, Germany); sanguinarine
(HPLC > 98%), chelerythrine chloride (HPLC > 98%),
homoharringtonine were purchased from Baoji Herbest
Bio-Tech Co., Ltd. (Baoji, Shannxi, China). Chelidonine
was purchased from PhytoLab GmbH & Co. KG (Vesten-
bergsgreuth, Germany). Doxorubicin hydrochloride (Dox-
o-cell, 2 mg/mL) from cell pharm GmbH (Bad Vilbel,
Germany). Dulbecco’s modified eagle’s medium (DMEM),
penicillin and streptomycin from Life Technologies (Bleis-
wijk, Netherlands). 96-well plates and 24-well plates came
from Greiner Bio-One GmbH (Frickenhausen, Germany).
Cell culture
U2OS human osteosarcoma cancer cells, which were
stably transfected with an α-tubulin-GFP construct, were
supplied by Prof. Dr. Thomas Efferth (Institute of Phar-
macy and Biochemistry, Johannes Gutenberg University,
Mainz, Germany). U2OS-GFP-α-tubulin cells were
grown in DMEM medium with 10% FBS, 1% penicillin
streptomycin and continuously treated with 250 μg/mL
geneticin at 37 °C and 5% CO2. All experiments were
performed with cells in their logarithmic growth phase.
MTT assay
The cytotoxicity of tested compounds was assessed using
the MTT assay, as previously described [16]. U2OS cells
(1 × 104 cells/well) were seeded in 96-well plates and
grown for 24 h. Then 100 μL fresh medium containing
serial dilutions of compounds was added into each well
and incubated for 48 h. All extracts were removed and
100 μL 0.5 mg/mL MTT solution was then added into
each well. After 2 h incubation, MTT was removed and
100 μL DMSO was added. The plate was shaken at 600
rpm for 15 min and the absorbance was read at 570 nm
using Tecan infinite M200 Pro (Tecan, Crailsheim,
Germany). Experiments were done in triplicate, repeated
three times. The IC50 values were calculated from
concentration-response curves by SigmaPlot software
(Systat Software Inc., San Jose, CA, USA). Data are pre-
sented as the mean ± standard deviation (SD).
In vitro wound healing assay
U2OS cells (3 × 105 cells/well) were seeded in 24-well
plates to grow in a monolayer for 24 h. Then a sterile
20–200 μL pipette tip was held vertically to scratch a
cross in each well. The detached cells were removed by
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washing with 500 μL PBS and shaking at 500 rpm for 5
min. 500 μL of fresh medium with or without diluted
samples was added afterwards and incubated for 72 h.
Before the image acquisition, the plate was washed with
500 μL pre-warmed PBS and gently shaken for 30 s.
Then, pre-warmed medium or sample was added again
and pictures were taken. The scratch closure was moni-
tored and imaged in 24 h intervals using a Keyence
BZ-9000 microscope (Keyence, Neu-Isenburg, Germany)
at 4 x magnification and 1/3700 s exposure time.
Analysis of open wound area
The analysis of the scratch images was performed using
the TScratch Version 1.0 software [37] which calculates
the scratch area (= open wound area) for each image.
The percentage of open wound area was plotted over
the time for each concentration. Data are presented as
mean ± SD. Three to six replicates were included in the
analysis and an unpaired Student’s t-test was performed.
Significance was considered at p < 0.05.
Fluorescence imaging
Fluorescence images of U2OS cells were taken each time
after the imaging of scratch closure using the BZ-9000
microscope at 40 x magnification. For the illumination and
image acquisition, the GFP channel was used and the mono-
chromatic image was displayed in the pseudo-color green.
Colchicine VinblastinePodophyllotoxin
Sanguinarine Chelerythrine Chelidonine
Homoharringtonine DoxorubicinPaclitaxel
Fig. 1 Structure of the substances tested in the study
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Results
Anti-proliferative activity of toxins
The anti-proliferative activity of reference drugs (vin-
blastine, colchicine and paclitaxel) and cytotoxic alka-
loids (sanguinarine, chelerythrine, chelidonine and
homoharringtonine) in U2OS cells has been previously
studied by us [22]. In this study, we included data on the
cytotoxicity of doxorubicin and podophyllotoxin
(Table 1). The known anti-tumor drug doxorubicin
inhibited the growth of U2OS cells with an IC50 value of
0.69 μM. The microtubule-binding natural products col-
chicine, vinblastine, podophyllotoxin and paclitaxel
showed more potent anti-proliferative activities than
doxorubicin with IC50 values between 0.1 nM and
0.23 μM. Vinblastine exhibited the strongest inhibition
with an IC50 value of 0.10 nM, whereas homoharringto-
nine caused the second strongest cytotoxicity with an
IC50 value of 3 nM. The benzophenanthridine alkaloids
sanguinarine, chelerythrine and chelidonine are also
cytotoxic; they inhibited the growth of U2OS cells with
IC50 values ranging between 0.92 μM and 3.86 μM.
Do selected alkaloids interfere with cell motility in vitro?
In the wound healing assay, we examined cell migration in
response to the mechanical scratch wound in the absence
or presence of putative inhibitors. Images of scratch areas
from the time points 0, 24, 48 and 72 h are illustrated in
Fig. 2. Figure 2a shows the representative control at each
time point indicating that the scratch was half closed
within 24 h and completely closed after 72 h.
To quantify the effects of putative migration inhibitors,
the percentage of the open wound area after 72 h was de-
termined (Table 2 and Fig. 3). Our data clearly shows that
treatment with homoharringtonine, doxorubicin and
microtubule-binding agents paclitaxel, vinblastine, colchi-
cine and podophyllotoxin caused a significant inhibition
of cell migration in a concentration-dependent manner.
Between concentrations of 10 μM and 80 nM, pacli-
taxel significantly inhibited the scratch closure after 48 h
and deformed the cell morphology. The effect of 16 nM
paclitaxel was less obvious, while no migration inhibition
were observed below 16 nM. Compared with paclitaxel,
vinblastine inhibited cell migration even stronger: it sig-
nificantly inhibited the scratch closure at a low concen-
tration of 8.8 nM, which also changed the cell shape
from irregular into round form within 24 h. No influence
on cell motility was observed after treatment with 0.88
nM and 0.088 nM vinblastine. The migration of cells
was impaired by colchicine at all applied concentrations,
ranging from 10 μM to 16 nM. Similar to colchicine,
10 μM to 16 nM podophyllotoxin also significantly inhib-
ited cell migration.
The benzophenanthridine alkaloids did not inhibit cell
motility: Even 5 μM sanguinarine did not disturb cell mi-
gration but it detached the cells from the bottom of the
culture flask within 24 h, making it impossible to deter-
mine the scratch size. No effect on cell motility and cell
morphology was recorded for sanguinarine concentra-
tions below 5 μM (Fig. 3e and Table 2).
Similar to sanguinarine, chelerythrine detached cells at
the highest applied concentration (12 μM) after 24 h of
incubation, which made it impossible to measure the
scratch area. Lower concentrations of chelerythrine
(< 12 μM) did not affect cell migration and morph-
ology significantly (Fig. 3f and Table 2).
Figure 3g indicates that 20 μM chelidonine might in-
hibit the scratch closure, however, this effect was not
statistically significant (Table 2). At this concentration,
chelidonine also detached cells and induced a change in
cell morphology. Below the concentration of 2 μM, che-
lidonine did not differ from the untreated control.
Similar to microtubule-binding agents, homoharring-
tonine inhibited the wound healing at low concentra-
tions; cells were completely detached from the flask
surface at a concentration of 8 μM after 48 h and 1.6 μM
after 72 h. However, the scratch closure was significantly
inhibited at the concentration of 12.8 nM (Table 2).
Treatment of the cells with 20 and 10 μM doxorubicin
caused inhibition of cell motility and change of cell
morphology within 24 h. Although the scratch usually
closed after the treatment with 5 μM doxorubicin, the
cell morphology showed changes after 48 h.
Do selected alkaloids interfere with microtubules in
living cells?
In order to determine whether the inhibition of cell mi-
gration caused by selected toxins was mediated by an al-
teration of microtubule dynamics, U2OS cells were
imaged under fluorescence microscopy. Figure 4 illus-
trates the dose dependence of each compound on the
microtubule network. In non-treated U2OS cells, the
Table 1 The cytotoxicity of selected natural products in
U2OS cells
Compounds IC50
Vinblastine 0.10 ± 0.05 nM
Homoharringtonine 3.00 ± 1.67 nM
Colchicine 10.67 ± 10.18 nM
Podophyllotoxin 33.6 ± 4.31 nM
Paclitaxel 0.23 ± 0.10 μM
Doxorubicin 0.69 ± 0.26 μM
Sanguinarine 0.92 ± 0.53 μM
Chelerythrine 2.88 ± 0.76 μM
Chelidonine 3.86 ± 1.99 μM
Data are presented as the mean ± standard deviation (SD).
Wang et al. BMC Pharmacology and Toxicology            (2019) 20:4 Page 4 of 12
Untreated cells
Scratch closure
0 h 24 h 48 h 72 hA
Paclitaxel
10000 nM
2000 nM
0 h 24 h 48 h 72 h
400 nM
80 nM
16 nM
1.6 nM
0.16 nM
B
Vinblastine
5500 nM
1100 nM
220 nM
44 nM
0 h 24 h 48 h 72 h
8.8 nM
0.88 nM
0.088 nM
C
Colchicine
10000 nM
0 h 24 h 48 h 72 h
2000 nM
400 nM
80 nM
16 nM
D
0 h 24 h 48 h 72 h
Podophyllotoxin 
10000 nM
2000 nM
400 nM
80 nM
16 nM
3.2 nM
0.64 nM
E
Sanguinarine
5000 nM
0 h 24 h 48 h 72 h
1000 nM
200 nM
40 nM
8 nM
F
0 h 24 h 48 h 72 h
Chelerythrine
12000 nM
2400 nM
480 nM
96 nM
19.2 nM
G
0 h 24 h 48 h 72 h
Chelidonine
20000 nM
4000 nM
800 nM
160 nM
32 nM
H
0 h 24 h 48 h 72 h
Homoharringtonine 
320 nM
64 nM
12.8 nM
2.56 nM
0.5 nM
I
0 h 24 h 48 h 72 h
Doxorubicin
20000 nM
10000 nM
5000 nM
2500 nM
1250 nM
J
Fig. 2 Time course of scratch closures with tested drugs. (a) Time course of scratch closure in the absence of drugs. The four upper images show
untreated cells, while the four lower images illustrate the size of the scratch area (analysis with TScratch software). (b - j) U2OS monolayers were
mechanically wounded with a 20–200 μL sterile pipette tip following treatment with tested alkaloids. Bar = 200 μm
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Table 2 Open scratch area of U2OS cells treated with putative migration inhibitors. The scratch area at time 0 was set 100%;
*** p < 0.001, ** p < 0.01, * p < 0.05; n = number of repetitions. / = cells detached from flask surface
Compound Concentration (nM) 24 h 48 h 72 h n
Paclitaxel Control 41.03 ± 27.83 11.91 ± 14.40 6.09 ± 8.54 6
10,000 75.67 ± 28.21 70.15 ± 25.93 *** 69.49 ± 25.96 *** 6
2000 64.68 ± 20.47 57.75 ± 17.49 *** 61.11 ± 17.56 *** 6
400 59.24 ± 16.44 53.24 ± 14.03 *** 54.84 ± 17.46 *** 6
80 58.47 ± 13.84 50.23 ± 13.39 *** 49.62 ± 14.53 *** 6
16 48.24 ± 12.56 30.49 ± 18.99 26.34 ± 18.47 * 6
1.6 42.11 ± 27.84 15.68 ± 11.85 4.79 ± 5.37 4
0.16 42.37 ± 19.51 12.86 ± 7.46 2.89 ± 4.23 3
Vinblastine Control 43.80 ± 32.59 10.22 ± 13.33 4.35 ± 6.95 4
5500 72.66 ± 19.76 57.06 ± 15.12 ** 70.21 ± 14.25 *** 4
1100 65.92 ± 31.03 58.11 ± 29.74 * 62.65 ± 36.28 * 4
220 67.60 ± 27.12 60.92 ± 23.69 ** 61.14 ± 22.50 ** 4
44 63.52 ± 28.10 55.48 ± 30.19 * 50.97 ± 33.90 * 4
8.8 69.83 ± 23.52 57.55 ± 30.94 * 55.31 ± 32.09 * 4
0.88 60.74 25.08 21.46 2
0.088 30.21 4.30 1.44 2
Colchicine Control 48.05 ± 24.45 14.30 ± 14.71 7.31 ± 8.94 5
10,000 68.25 ± 24.54 61.62 ± 34.50 * 63.70 ± 33.17 ** 5
2000 60.03 ± 25.98 47.87 ± 23.46 * 51.51 ± 32.26 * 5
400 51.41 ± 25.58 45.61 ± 24.09 * 42.70 ± 27.24 * 5
80 57.52 ± 23.55 52.54 ± 21.60 * 49.97 ± 27.97 * 5
16 48.62 ± 25.82 37.68 ± 25.16 37.71 ± 26.11 * 5
Compound Concentration (nM) 24 h 48 h 72 h n
Podophyllo-
toxin
Control 11.66 ± 3.82 2.22 ± 2.36 0.43 ± 0.75 3
10,000 65.10 ± 4.24 *** 76.78 ± 1.37 *** 71.37 ± 5.90 *** 3
2000 70.81 ± 28.15 * 66.87 ± 15.93 ** 84.08 ± 18.24 ** 3
400 58.66 ± 6.67 *** 60.56 ± 2.13 *** 63.58 ± 12.85 ** 3
80 66.88 ± 6.17 *** 62.97 ± 5.34 *** 79.59 ± 14.17 *** 3
16 42.41 ± 1.51 *** 34.57 ± 10.57 ** 52.73 ± 8.81 *** 3
3.2 10.45 ± 14.19 0 0 3
0.64 15.70 ± 22.11 0 0 3
Sanguinarine Control 39.69 ± 13.67 10.73 ± 10.21 4.19 ± 7.67 4
5000 / / / 5
1000 39.62 ± 12.17 19.70 ± 5.54 13.10 ± 5.47 5
200 35.96 ± 18.07 18.12 ± 20.85 13.96 ± 20.04 5
40 29.66 ± 7.64 6.43 ± 7.75 4.37 ± 6.48 5
8 28.96 ± 15.04 5.07 ± 7.42 2.39 ± 4.84 5
Chelerythrine Control 39.69 ± 13.67 10.73 ± 10.21 4.19 ± 7.67 4
12,000 84.35 ± 23.35 * / / 5
2400 34.43 ± 12.35 10.83 ± 14.73 9.34 ± 16.31 5
480 42.79 ± 13.29 15.89 ± 19.22 10.02 ± 18.69 5
96 29.69 ± 18.00 11.70 ± 21.10 9.28 ± 19.95 5
19.5 30.33 ± 17.73 9.07 ± 18.47 7.64 ± 16.94 5
Wang et al. BMC Pharmacology and Toxicology            (2019) 20:4 Page 6 of 12
microtubules extended continuously through the cyto-
plasm and formed an extensive intracellular network
with the exception of the nuclear region (Fig. 4a).
Microtubule-binding agents which significantly inhibited
cell motility in previous experiment, also affected microtu-
bules in living U2OS cells. The microtubule-stabilizer pacli-
taxel promoted the polymerization of microtubules with
the brightness and thickness increased over time (Fig. 4c).
The microtubule morphology was changed after the treat-
ment with 1.6 nM paclitaxel, which had no effect on cell
migration.
Treatment with microtubule-destabilizers induced micro-
tubule depolymerization. 8.8 nM and 5.5 μM vinblastine ex-
tensively reduced the mass and depolymerized the network
of microtubules (Fig. 4d). These concentrations also inhib-
ited the cell motility. At a concentration of 5.5 μM, tubulin
paracrystals were formed and dispersed through the cyto-
plasm. Cells treated with vinblastine were seen to lose their
cellular protrusions and changed their morphology. This ef-
fect was even visible at low concentrations (0.88 nM and
0.088 nM) that did not affect cell migration, with the ap-
pearance of multi-nucleated cells.
Except for the formation of tubulin paracrystals, colchicine
showed similar effects on microtubules as vinblastine.
Colchicine mainly reduced the mass of the microtubule net-
work which appeared less dense at the cell periphery com-
pared to the cells at the start of the experiment (Fig. 4b).
Podophyllotoxin exhibited a similar effect as colchicine; the
mass of microtubule network was decreased and the cell
morphology was changed (Fig. 4e).
Though the benzophenanthridine alkaloids did not
significantly inhibit cell migration, they influenced the
microtubule network to some extent. Sanguinarine ap-
peared to reduce the mass of microtubule network and
to change the cell morphology with concentrations in-
creased (Fig. 4f ). Compared to other substances, 12 μM
chelerythrine exerted a stronger effect on microtubules
in that the microtubule network was apparently dis-
rupted and depolymerized within minutes (Fig. 4g 0h),
which finally led to apoptosis. At lower concentrations,
chelerythrine exhibited similar effects on microtubules
as sanguinarine. Similar to colchicine and podophyllo-
toxin, chelidonine mainly decreased microtubule mass at
the cell periphery at all applied concentrations (Fig. 4h).
The treatment of homoharringtonine (Fig. 4i) signifi-
cantly changed cell morphology and reduced micro-
tubule mass at the concentrations (12.8 nM – 8 μM) that
also interfered with cell motility. Below 12.8 nM, the cell
Table 2 Open scratch area of U2OS cells treated with putative migration inhibitors. The scratch area at time 0 was set 100%;
*** p < 0.001, ** p < 0.01, * p < 0.05; n = number of repetitions. / = cells detached from flask surface (Continued)
Compound Concentration (nM) 24 h 48 h 72 h n
Chelidonine Control 44.80 ± 16.45 20.16 ± 22.85 14.38 ± 23.73 5
20,000 57.98 ± 11.72 43.41 ± 24.82 44.06 ± 30.05 5
4000 44.59 ± 15.78 25.26 ± 23.38 24.46 ± 31.62 5
800 45.80 ± 17.05 23.94 ± 23.20 21.03 ± 24.67 5
160 39.21 ± 12.32 15.26 ± 15.19 12.04 ± 16.10 5
32 30.50 ± 14.01 7.77 ± 11.29 8.22 ± 16.72 5
Homoharring-
tonine
Control 3.76 ± 2.83 0.31 ± 0.69 0.26 ± 0.58 3
8000 78.98 ± 12.39 *** / / 3
1600 74.23 ± 20.66 ** 68.25 ± 15.17 ** / 3
320 70.09 ± 6.42 *** 72.37 ± 7.95 *** 75.60 ± 7.17 *** 3
64 85.25 ± 16.02 *** 86.73 ± 12.13 *** 83.94 ± 12.26 *** 3
12.8 39.11 ± 7.84 ** 28.99 ± 6.44 ** 29.76 ± 7.19 ** 3
2.56 13.45 ± 5.53 2.68 ± 3.97 1.95 ± 3.38 3
0.5 19.08 ± 5.65 * 4.31 ± 1.71 3.95 ± 3.51 3
0.1 2.18 ± 0.85 0 0 3
Doxorubicin Control 30.29 ± 15.09 5.06 ± 4.76 0.36 ± 0.62 3
20,000 86.77 ± 11.70 ** 94.33 ± 5.34 *** / 3
10,000 71.22 ± 4.93 * 76.25 ± 6.40 *** 73.47 ± 4.82 *** 3
5000 31.19 ± 2.67 11.32 ± 6.42 7.27 ± 4.59 3
2500 27.93 ± 17.02 6.43 ± 7.73 0.65 ± 1.12 3
1250 21.82 ± 17.07 4.76 ± 6.55 0.58 ± 1.01 3
Data are presented as the mean ± SD.
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morphology and microtubule mass were slightly altered
by homoharringtonine.
Doxorubicin (Fig. 4j) exhibited strong effects both on
cell morphology and reduction of microtubule mass at
high applied concentrations (1.25–20 μM). Below con-
centrations of IC50 (0.3–0.6 μM), no obvious changes
were observed on microtubules and cell morphology.
Discussion
The present study elucidated the effects of nine cytotoxic
natural products on cell migration and their putative interac-
tions with microtubules. Doxorubicin, homoharrigtonine and
microtubule-binding agents paclitaxel, vinblastine, colchicine
and podophyllotoxin significantly inhibited cell migration,
but not the benzophenanthridine alkaloid sanguinarine, che-
lerythrine and chelidonine. In addition, all substances exhib-
ited certain effects on microtubules.
Paclitaxel, vinblastine, colchicine and podophyllotoxin
are known as MBAs that stabilize or destabilize microtu-
bules. Our previous study [38] had demonstrated that
paclitaxel, vinblastine and colchicine alter microtubule
dynamic both in living cells and in vitro. In present
study, the interaction between these substances and cel-
lular microtubules was further investigated (Fig. 4b-e),
which is in accordance with our previous findings. Here
we further provide evidence that podophyllotoxin inhib-
ited tubulin polymerization in vitro with IC50 value of
2.04 μM (Additional file 1: Table S1 and Additional file 2:
Figure S1), indicating its mode of action consists with col-
chicine, vinblastine and paclitaxel. In addition, these
MBAs also inhibited cell migration at the concentrations
which were lower than those causing cytotoxicity. Pacli-
taxel has been reported to inhibit cell migration at
concentrations that significantly suppress microtubule dy-
namics without modifying the microtubule mass, which
limited the number of microtubule plus ends to regulate
the formation of lamellipodia. Belotti D et al. [39] also
demonstrated that the anti-migratory effect of paclitaxel
occurs at non anti-proliferative concentrations in tumor
cells. Vinblastine was also found to suppress both dynamic
instability and cell migration at low concentration, but
higher drug concentrations are needed to inhibit micro-
tubule assembly and cell division [22]. Our observations
are in accordance with these published data, which
Fig. 3 The relative size of open scratch area. (a - i) The open wound area was measured after the treatment of tested alkaloids. The scratch area
of untreated cells is set to 100%. * p < 0.05, ** p < 0.01, *** p < 0.001
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2 µM
400 nM
80 nM
16 nM
0 h 24 h 48 h 72 hB
0 h 24 h 48 h 72 h
Non-treated 
U2OS cells
A
Paclitaxel
10 µM
2 µM
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C
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Fig. 4 Representative fluorescence images of U2OS cells treated with tested substances. In U2OS cells microtubules carry a GFP label which
allowed to visualize the microtubule network. Panels show micrographs of U2OS cells treated for 0 h, 24 h, 48 h and 72 h without (a) or with
(b - j) tested alkaloids at different concentrations. Bar = 30 μm
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indicates the potential ability of MBAs to act as effective
anti-migrating agents. MBAs inhibit cell motility by interfer-
ence with microtubule dynamics, preventing the activation
of Rac1/Cdc42 and disorganizing the actin cytoskeleton [40].
Consistent with recent studies [38, 41], benzophenanthri-
dine alkaloid sanguinarine, chelerythrine and chelidonine
were found to affect microtubule network and change the
cell morphology in U2OS cells (Fig. 4f-h), further demon-
strating that an interaction occurs between benzophenan-
thridine alkaloids and microtubules. We have previously
reported that sanguinarine and chelerythrine which inhib-
ited microtubule polymerization in vitro, did not cause
mitotic arrest [38]. In the present study, we found that
sanguinarine, and chelerythrine did not inhibit the migra-
tion of U2OS cells like other microtubule-binding agents
(Table 2), which agrees with the previous assumption that
the mode of sanguinarine and chelerythrine differs from
that of microtubule-binding agents. Furthermore, the
microtubule dynamics are probably not their main cause
to induce apoptosis. Chelidonine, which altered micro-
tubule dynamics and induced mitotic arrest in the previ-
ous study [38], did not significantly inhibit cell migration.
In contrast to our findings, several authors have reported
the inhibition of migration by benzophenanthridine alka-
loids. JP Eun and GY Koh [42] found that sanguinarine
inhibited cell migration in endothelial cells by blocking
VEGF-induced Akt activation; I Tan et al. [43] have no-
ticed that chelerythrine inhibited the speed of migration
in U2OS cells by blocking cellular activity of MRCK; O
Kim et al. [44] reported that chelidonine suppressed mi-
gration and invasion of MDA-MB-231 cells by inhibiting
formation of the integrin-linked kinase/PINCH/α-parvin
complex. So how can we explain this discrepancy? Differ-
ent types of cells contain specific factors which may
modulate their sensitivities to these alkaloids. In addition,
sanguinarine, chelerythrine and chelidonine affect mul-
tiple targets such as DNA (intercalation), protein kinase C
(inhibitor) and telomerase (inhibitor) etc. The specific fac-
tors of cancer cells and the multiple targets of these alka-
loids therefore result in various responses in different cell
types, which requires further systematic research to
understand the anticancer properties of this class of com-
pounds and the pathways that lead to apoptosis.
Homoharringtonine is a known protein synthesis inhibi-
tor that has been used clinically to treat chronic myeloid
leukemia [45, 46]. Homoharringtonine displayed the sec-
ond strongest cytotoxicity among the tested compounds
during the study. In addition, homoharringtonine signifi-
cantly inhibited cell migration in the wound healing assay,
which has been reported for the first time. At high applied
concentrations, homoharringtonine exhibited strong ef-
fects on cell morphology and microtubule mass. However,
disruption of tubulin polymerization and cell cycle are not
involved in the mechanisms of homoharringtonine [38].
Thus, a probable explanation might be that the inhibition
of protein biosynthesis would also prevent the synthesis of
proteins related to the cytoskeleton.
Doxorubicin is an anthracycline antibiotic that has been
commonly used in the cancer treatment for more than 40
years [34, 47]. Doxorubicin is known to induce various se-
vere side effects in clinical application including poor
wound healing [48, 49]. In this study, we observed that
doxorubicin inhibited cell migration, altered cell morph-
ology, and reduced microtubule mass at high cytotoxic con-
centrations in U2OS cells, which could explain these
clinical reports. However, doxorubicin did not show impact
on tubulin assembly in vitro (Additional file 1: Table S1), in-
dicating that direct effects on microtubules are not involved
in its mechanism. Doxorubicin impaired cell migration
probably via the inhibition of protein synthesis and prolyl
4-hydroxylase [49]. Generally, doxorubicin could be re-
ferred as an anti-migrating agent but its clinical admin-
istration should be further studied and more research is
needed to improve the therapeutic efficiency and de-
crease its side effects.
Conclusions
This study investigated the roles of cytotoxic alkaloids in
biological processes related to cell migration and cytoskel-
eton dynamics. In conclusion, we found that: (1) MBAs
are effective anti-migrating agents; (2) the benzophenan-
thridine alkaloid sanguinarine, chelerythrine and chelido-
nine did not inhibit cell migration; (3) homoharringtonine
and doxorubicin can be referred as anti-migrating agents,
but direct microtubule dynamics are not involved in their
mode of action. Our study emphasize the link between
microtubule inhibitors and inhibition of cell migration.
More studies at a molecular level are necessary to under-
stand the exact role of microtubule inhibitors in cell inva-
sions and metastasis.
Additional files
Additional file 1: Table S1. The IC50 values of podophyllotoxin and
doxorubicin on tubulin polymerization. Each experiment was
independently performed three times. (DOCX 14 kb)
Additional file 2: Figure S1. Podophyllotoxin inhibited tubulin
polymerization in vitro. In-Vitro tubulin polymerization assay was per-
formed according to a standard protocol (Reference 16). Polymerization
of tubulin with MAPs in the assembly buffer was measured in the absence
(◆) and in the presence of different concentrations of podophyllotoxin.
Podophyllotoxin significantly inhibited the nucleation and growth phase
during microtubule assembly. (DOCX 59 kb)
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